Payment overview · 2025
General Payments
$228.14
11 reported records · 6 companies
Healthcare provider profile · identity verified
Eric D Shoemaker, MD
Allopathic & Osteopathic Physicians|Family Medicine · CASS CITY, MI · NPI 1598285926
Verified facts
What the public records show
CMS Open Payments records show Eric D Shoemaker, MD received $228.14 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.79 | 32.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.80 | 22.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.34 | 17.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.49 | 10.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.02 | 9.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.70 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.14 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.80 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 438 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 104 |
| Losartan Potassium | Losartan Potassium | 294 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 80 |
| Omeprazole | Omeprazole | 270 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 72 |
| Famotidine | Famotidine | 250 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 70 |
| Lisinopril | Lisinopril | 179 | 60 |
| Potassium Chloride | Potassium Chloride | 170 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 45 |
| Eliquis | Apixaban | 161 | 43 |
| Montelukast Sodium | Montelukast Sodium | 161 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 62 |
| Gabapentin | Gabapentin | 146 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 39 |
| Metformin Hcl Er | Metformin Hcl | 134 | 41 |
| Meloxicam | Meloxicam | 126 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 37 |
| Furosemide | Furosemide | 120 | 46 |
| Metformin Hcl | Metformin Hcl | 120 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 58 |
| Spironolactone | Spironolactone | 101 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 34 |
| Trazodone Hcl | Trazodone Hcl | 100 | 39 |
| Pregabalin | Pregabalin | 98 | 23 |
| Prednisone | Prednisone | 97 | 50 |
| Simvastatin | Simvastatin | 93 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 27 |
| Jardiance | Empagliflozin | 90 | 29 |
| Allopurinol | Allopurinol | 87 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 18 |
| Clonazepam | Clonazepam | 67 | 11 |
| Ezetimibe | Ezetimibe | 67 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 17 |
| Carvedilol | Carvedilol | 65 | 16 |
| Ibuprofen | Ibuprofen | 65 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 19 |
| Atenolol | Atenolol | 62 | 16 |
| Bumetanide | Bumetanide | 61 | 19 |
| Cephalexin | Cephalexin | 57 | 34 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | 19 |
| Nystatin | Nystatin | 46 | 16 |
| Tramadol Hcl | Tramadol Hcl | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 14 |
| Ozempic | Semaglutide | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 27 |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 16 |
| Naproxen | Naproxen | 41 | 11 |
| Mirtazapine | Mirtazapine | 39 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 14 |
| Valsartan | Valsartan | 39 | 11 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Azithromycin | Azithromycin | 36 | 28 |
| Ondansetron Odt | Ondansetron | 36 | 17 |
| Bupropion Xl | Bupropion Hcl | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 15 |
| Celecoxib | Celecoxib | 33 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Alprazolam | Alprazolam | 27 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 16 |
| Ramelteon | Ramelteon | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.14 · 11 records | Novo Nordisk Inc | AUSTEDO XR, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error